

Editorial – Announcing changes in the Editorial Board

C. RICORDI

Diabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, FL, USA

It is with the highest degree of enthusiasm that I accept the transition from the Senior Editorial Board to Editor in Chief of *European Review for Medical and Pharmacological Sciences*. I am honored to succeed my admired friend and colleague, Prof. Antonio Gasbarrini and Prof. Aldo V. Greco, who have been associated with this prestigious journal for so many years. I would like to thank them and their distinguished collaborators for their exceptional contributions during all these years.

I am thankful also to the Assistant Editors and the entire Editorial Board, the reviewers, and the editorial staff at Verduci Editore, but most of all I would like to thank all our Authors, who with their scientific contributions are the ones ultimately responsible for the significant growth of the Journal, as reflected in the progressive growth of Impact Factor and Citations (Figure 1).

Please join me welcoming my new Coeditor in Chief, Prof. David Della Morte Canosci, a long-term friend and distinguished collaborator of mine, both in Europe and in the USA.

Please welcome also the new additions to the Editorial Board, Prof. Nicola Di Daniele as Associate Editor, Dr. Marco Infante, Dr. Francesca Pacifici, Dr. Davide Lauro, Dr. Fiorella Guadagni, Dr. Valentina Rovella, Dr. Annalisa Noce and Dr. Ambrogio Capria who together with the rest of the distinguished Editorial Board, will assist with the evaluation of the manuscripts. Our major objective remains to ensure that manuscripts will undergo a rigorous review process while allowing timely publications from our growing body of manuscript submissions from distinguished international Authors.

I would also like to thank our large team of reviewers, who will continue to be the pillars of our journal and its rigorous peer-review process.

It is only with quality of papers and transparent editorial practices that we will continue to witness renewed success and growth of Eur Rev Med Pharmacol Sci, as a reliable source of information for our readers.




Figure 1. Eur Rev Med Pharmacol Sci metrics.